Olfactomedin-4(OLFM4, GW112, h GC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. P...Olfactomedin-4(OLFM4, GW112, h GC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. Previous studies have revealed that OLFM4 is closely associated with many digestive diseases. Up-regulation of OLFM4 has been detected in the Helicobacter pylori(H. pylori)-infected gastric mucosa, inflammatory bowel disease tissue and gastrointestinal malignancies, including gastric cancer, colorectal cancer, pancreatic cancer and gallbladder cancer. Downregulation of OLFM4 has also been detected in some cases, such as in poorly differentiated, advancedstage and metastatic tumors. Studies using OLFM4-deficient mouse models have revealed that OLFM4 acts as a negative regulator of H. pylori-specific immune responses and plays an important role in mucosal defense in inflammatory bowel disease. Patients with OLFM4-positive gastric cancer or colorectal cancer have a better survival rate than OLFM4-negative patients. However, the prognosis is worse in pancreatic cancer patients with high levels of expression of OLFM4. The NF-κB, Notch and Wnt signaling pathways are involved in the regulation of OLFM4 expression in digestive diseases, and its role in pathogenesis is associated with anti-inflammation, apoptosis, cell adhesion and proliferation. OLFM4 may serve as a potential specific diagnostic marker and a therapeutic target in digestive diseases. Further studies are required to explore the clinical value of OLFM4.展开更多
基金Supported by the National Natural Science Foundation of China,No.81470838the Science Foundation of Health Bureau of Zhejiang Province,No.2015KYB030
文摘Olfactomedin-4(OLFM4, GW112, h GC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. Previous studies have revealed that OLFM4 is closely associated with many digestive diseases. Up-regulation of OLFM4 has been detected in the Helicobacter pylori(H. pylori)-infected gastric mucosa, inflammatory bowel disease tissue and gastrointestinal malignancies, including gastric cancer, colorectal cancer, pancreatic cancer and gallbladder cancer. Downregulation of OLFM4 has also been detected in some cases, such as in poorly differentiated, advancedstage and metastatic tumors. Studies using OLFM4-deficient mouse models have revealed that OLFM4 acts as a negative regulator of H. pylori-specific immune responses and plays an important role in mucosal defense in inflammatory bowel disease. Patients with OLFM4-positive gastric cancer or colorectal cancer have a better survival rate than OLFM4-negative patients. However, the prognosis is worse in pancreatic cancer patients with high levels of expression of OLFM4. The NF-κB, Notch and Wnt signaling pathways are involved in the regulation of OLFM4 expression in digestive diseases, and its role in pathogenesis is associated with anti-inflammation, apoptosis, cell adhesion and proliferation. OLFM4 may serve as a potential specific diagnostic marker and a therapeutic target in digestive diseases. Further studies are required to explore the clinical value of OLFM4.
文摘目的:观察葛根芩连汤辅助0.1%糠酸莫米松乳膏及盐酸西替利嗪片治疗特应性皮炎(Atopic dermatitis,AD)患者的临床疗效以及血清中神经生长因子(Nerve growth factor,NGF)和神经营养因子4(Neurotrophin-4,NT-4)水平的影响。方法:选取2021年5月-2023年5月收入笔者医院的AD患者60例,根据治疗方案的差异随机分为对照组(西药治疗)、观察组(西药治疗+中药辅助治疗)每组30例。对照组采用外用糠酸莫米松乳膏,口服盐酸西替利嗪进行干预治疗,观察组在对照组基础上采用葛根芩连汤辅助进行治疗。观察两组患者治疗前、后血清中NGF、NT-4水平、瘙痒视觉模拟评分(Visual analogue scale,VAS)、湿疹面积及严重指数(Eczema area and severity index,EASI)评分,治疗后临床疗效及不良反应发生率。结果:治疗前两组患者血清中NGF、NT-4水平、VAS评分、EASI评分相比差异无统计学意义(P>0.05),经治疗后两组患者血清中NGF、NT-4水平、VAS评分、EASI评分均较同组治疗前显著降低(P<0.05),且观察组优于对照组(P<0.05);经治疗后,观察组患者临床疗效总有效率高于对照组,不良反应发生率低于对照组(P<0.05)。结论:葛根芩连汤辅助西药治疗AD可下调患者血清中NGF、NT-4水平,减轻瘙痒症状及皮损程度,改善临床症状,降低不良事件的发生率,值得临床推广应用。
